Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease ; volume:14 ; number:1 ; day:19 ; month:4 ; year:2022 ; pages:1-16 ; date:12.2022
Alzheimer's research & therapy ; 14, Heft 1 (19.4.2022), 1-16, 12.2022
- Creator
-
Assunção, Sheila Seleri
Sperling, Reisa A.
Ritchie, Craig
Kerwin, Diana R.
Aisen, Paul S.
Lansdall, Claire
Atri, Alireza
Cummings, Jeffrey
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-022-00984-y
- URN
-
urn:nbn:de:101:1-2022070220214301394030
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Assunção, Sheila Seleri
- Sperling, Reisa A.
- Ritchie, Craig
- Kerwin, Diana R.
- Aisen, Paul S.
- Lansdall, Claire
- Atri, Alireza
- Cummings, Jeffrey
- SpringerLink (Online service)
Other Objects (12)
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease
Optimising Alzheimer’s Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
A Simulation Model to Evaluate the Potential Impact of Disease-Modifying Treatments on Burden of Illness in Alzheimer’s Disease